Corporate Profile

We are a clinical-stage biotechnology company that seeks to discover, develop and commercialize novel therapies capable of transforming treatment paradigms in the management of serious medical conditions.

Read More

Stock Information

EDGE (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$0.79
Change (%) Stock is Up 0.05 (6.76%)
Volume4,129
Data as of September 24, 2018 11:15 a.m. ET
Refresh quote

IR Contact

Gregory Gin
Email: ir@edgetherapeutics.com

More >>

Lastest News

August 1, 2018 - Edge Therapeutics Reports Second Quarter 2018 Financial Results
Read More
June 27, 2018 - Edge Therapeutics Announces Updated Results from Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Read More
May 1, 2018 - Edge Therapeutics Reports First Quarter 2018 Financial Results
Read More

More >>

Data provided by Nasdaq. Minimum 15 minutes delayed.

Printer Friendly Version Print PageE-mail this page Email PageRSS RSS FeedsE-mail Alerts Email AlertsView contacts IR Contacts